Jackson Acquisition Company II (JACS-RI)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | - | - | 0 | 0 | 0 | - |
| Operating profit | $m | -1 | -1 | ||||||
| Net profit | $m | - | - | - | - | 0 | 9 | 9 | - |
| EPS reported | $ | 0.31 | 0.30 | ||||||
| Operating cashflow per share | $ | -0.02 | -0.02 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.02 | -0.02 | ||||||
| Free cash flow | $m | -0 | -0 | ||||||
| Net debt | $m | -0 | -0 | ||||||
| Book value equity | $m | 243 | 247 | ||||||
| Book value per share | $ | 10.55 | 10.73 | ||||||
| Number of shares | m | 23 | 23 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 0.81 | 0.17 | ||||||
| P/B LTM | x | 0.99 | 0.97 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -560.49 | -659.63 | ||||||
| EV/EBITDA LTM | x | -420.54 | -408.00 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | +123.46% | +588.24% | ||||||
| FCF Yield | % | -0.18% | -0.15% | ||||||
| Quality | |||||||||
| ROE | % | +3.75% | +3.50% | ||||||
| ROIC | % | -0.23% | -0.24% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +2303.1% | +2225.6% | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | +2292.0% | +2135.5% | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -2.16 | -1.83 | ||||||
| Net Debt/EBITDA | x | 0.57 | 0.27 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +0.08% | +0.06% | ||||||
| Net debt/Equity | x | -0.00 | -0.00 | ||||||
| Gross debt/equity | x | 0.00 | 0.00 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Jackson Acquisition Company II (JACS-RI) operates as a special purpose acquisition company (SPAC), guided by a leadership team with extensive experience across the healthcare and consumer industries. This "blank check" entity was established with the primary objective of identifying, acquiring, and subsequently managing a promising business. The ideal target enterprise will be one poised to significantly benefit from the team's profound operational expertise and wide-reaching strategic connections. The firm's focus is on collaborating with a company that possesses a proven and successful business strategy, a formidable position within its market, and considerable potential for generating increased shareholder value once it has publicly listed.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Jackson Acquisition Company II (JACS-RI)
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Jackson Acquisition Company II (JACS-RI) operates as a special purpose acquisition company (SPAC), guided by a leadership team with extensive experience across the healthcare and consumer industries. This "blank check" entity was established with the primary objective of identifying, acquiring, and subsequently managing a promising business. The ideal target enterprise will be one poised to significantly benefit from the team's profound operational expertise and wide-reaching strategic connections. The firm's focus is on collaborating with a company that possesses a proven and successful business strategy, a formidable position within its market, and considerable potential for generating increased shareholder value once it has publicly listed.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free